B
Brenig Therapeutics
Brenig Therapeutics works on creating treatments for neurodegenerative disorders
About Brenig Therapeutics
Brenig Therapeutics is a clinical-stage biotechnology company developing small-molecule therapies for neurodegenerative conditions, with an initial focus on Parkinson's disease. Founded in 2021 through a collaboration between OrbiMed, Torrey Pines, and BGV, the company aims to create treatments that address the underlying causes of these complex disorders. Brenig's business model is centered on leveraging a proprietary AI/ML-based discovery platform, through a partnership with Expert Systems Inc., to design and advance a portfolio of drug candidates. The company's revenue generation will depend on the successful clinical development and eventual commercialization or out-licensing of its therapeutic assets.
The company is led by President and CEO David Lucchino, an executive with over two decades of experience in the life sciences sector, having previously co-founded and led companies like Frequency Therapeutics and Semprus BioSciences. The leadership team also includes Chief Medical Officer Dr. Tien Dam, who brings extensive expertise in neurodegenerative disease clinical development from her prior roles, including Head of Movement Disorders at Biogen. In July 2024, Brenig secured a significant milestone with a $65 million Series A financing round led by New Enterprise Associates (NEA), with participation from existing investors OrbiMed, Torrey Pines Investments, and BioGeneration Ventures. This capital is intended to advance its lead programs into and through human clinical trials.
Brenig's lead drug candidate, BT-267, is a small-molecule inhibitor targeting LRRK2, a key protein linked to the genetic causes of Parkinson's disease. Developed using the company's AI-driven models, BT-267 is engineered for high brain penetration and sustained exposure while minimizing peripheral activity to reduce potential side effects. Preclinical studies have confirmed a clean safety profile, and the company plans to advance BT-267 into clinical trials. The company's pipeline also includes BT-409, a CNS-penetrant small-molecule inhibitor of the NLRP3 inflammasome, which is another target for Parkinson's disease. BT-409 is being investigated for its potential across other neuro-inflammatory conditions such as multiple sclerosis and Alzheimer's disease, with plans to enter Phase 1 safety studies in 2025.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Somerville, United States
- Employees
- 4
- Open positions
- None listed
- Dealroom signal
- 59.4/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Jul 2024 | $65M | $260M | BioGeneration Ventures · Torrey Pines Investment · OrbiMed · NEA | ↗ |
Growth signals
Latest recorded traffic for Brenig Therapeutics is 1.3K monthly website visits, up 78.1% over the last three months. Brenig Therapeutics's team grew 300% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Brenig Therapeutics in the Somerville ecosystem
The Brenig Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
NEA
BioGeneration Ventures
Torrey Pines Investment
OrbiMed
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Brenig Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Brenig Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








